Oncotelic Therapeutics, Inc.: 10-Q filed 2026-05-14
What Oncotelic Therapeutics, Inc. reported in its quarterly report filed 2026-05-14 (fiscal Q1 2026): 29 published measures, 59 facts as tagged in accession 0001493152-26-023181.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-05-14
- Fiscal period
- fiscal Q1 2026
- Accession
- 0001493152-26-023181 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Oncotelic Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 393,955,039 | USD | |
| At 2025-12-31 | 393,088,242 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 131,743,498 | USD | |
| At 2025-12-31 | 131,356,683 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 263,286,077 | USD | |
| At 2025-12-31 | 262,760,595 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -2,193,776 | USD | 90 |
| 2025-01-01 to 2025-12-31 | 249,300,000 | USD | 365 |
| 2025-01-01 to 2025-03-31 | -298,716 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -342,243 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -166,955 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 317,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 160,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 209,045,388 | USD | |
| At 2025-12-31 | 211,239,164 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 443,801,416 | shares | 90 |
| 2025-01-01 to 2025-03-31 | 407,423,329 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 443,801,416 | shares | 90 |
| 2025-01-01 to 2025-03-31 | 407,423,329 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 0 | USD/shares | 90 |
| 2025-01-01 to 2025-03-31 | 0 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 0 | USD/shares | 90 |
| 2025-01-01 to 2025-03-31 | 0 | USD/shares | 90 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 1,641,847 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -1,853,385 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -101,100 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 2,065,049 | USD | |
| At 2025-12-31 | 1,198,252 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 18,403,989 | USD | |
| At 2025-12-31 | 18,143,278 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 2,788,230 | USD | |
| At 2025-12-31 | 2,788,230 | USD | |
| At 2024-12-31 | 2,788,230 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 2,058 | USD | |
| At 2025-12-31 | 51,324 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 1,853,385 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 101,100 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 795 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 297 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 444,197,302 | shares | |
| At 2025-12-31 | 442,596,856 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 49,798,210 | USD | |
| At 2025-12-31 | 47,095,219 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 262,211,541 | USD | |
| At 2025-12-31 | 261,731,559 | USD | |
| At 2025-03-31 | 7,183,446 | USD | |
| At 2024-12-31 | 7,477,512 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 1,979,377 | USD | |
| At 2025-12-31 | 1,038,071 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -2,239,276 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -364,264 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 1,852,590 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 100,803 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -385,891 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -263,164 | USD | 90 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-12-31 | 111,600,000 | USD | 365 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 118,683 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 94,773 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -49,266 | USD | 90 |
Inspect the source
- Entity
- Oncotelic Therapeutics, Inc. / CIK 0000908259
- Captured
- 2026-09-20T05:05:47.535Z
- SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))